SCHEDULE: Deep Track Capital Exits Jade Biosciences Stake

Deep Track Capital and its affiliates have reported a complete divestment of their beneficial ownership in Jade Biosciences, Inc.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an Amendment No. 2 to Schedule 13G.
• The reporting persons now beneficially own 0 shares of Jade Biosciences, Inc. Common Stock.
• This represents 0% of the class of securities outstanding.
• The event requiring this filing occurred on December 31, 2025.
• The beneficial ownership is determined based on 46,004,205 Common Stock outstanding as of November 7, 2025, as reported in Jade Biosciences' 10-Q filing on November 14, 2025.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a significantly negative development. The complete divestment by a specialized institutional investor typically signals a lack of confidence in the company's future performance or strategic direction.

Negatives

• Deep Track Capital, a significant institutional investor, has fully divested its stake in Jade Biosciences, Inc.
• The complete exit by a major investor could signal a lack of confidence in the company's future prospects.

Risks

• The complete divestment by a significant institutional investor like Deep Track Capital could lead to negative market sentiment and potential share price decline for Jade Biosciences, Inc.
• A lack of institutional backing may make it harder for Jade Biosciences to attract new capital or maintain investor confidence.

Future Outlook

No forward-looking statements or guidance are provided by the issuer in this ownership disclosure filing.

Industry Context

StockSavvy.ai notes that the complete exit of a specialized biotechnology investment fund like Deep Track Capital from a biotech company often raises questions about the company's long-term prospects or recent developments. In the volatile biotech sector, institutional investor confidence is a critical indicator, and a full divestment can be interpreted negatively by the market, potentially signaling concerns about clinical trial outcomes, regulatory hurdles, or competitive landscape shifts that are not explicitly stated in this filing.

Comparison to Industry Standards

• The divestment by Deep Track Capital, a fund known for its focus on biotechnology, suggests a re-evaluation of Jade Biosciences' investment thesis. This contrasts with typical long-term holdings seen in successful biotech ventures where institutional investors often increase stakes as milestones are met.
• Compared to peers in the early-stage biotech space, a significant institutional exit can be a more pronounced negative signal, as these companies often rely heavily on institutional capital and endorsement for their valuation and future funding rounds.

Stakeholder Impact

• Shareholders: Existing shareholders may experience negative sentiment and potential downward pressure on the stock price due to the exit of a major institutional investor.
• Potential Investors: New investors may be deterred by the lack of institutional backing, making it harder for the company to attract capital.

Key Dates

Recommendation

The complete divestment by a specialized institutional investor like Deep Track Capital is a strong negative signal. It suggests that a sophisticated investor, after thorough due diligence, has decided to fully exit their position, which often precedes or reflects underlying issues not yet fully public. This action warrants a 'strong sell' recommendation for existing holders and advises against new positions, as it indicates a significant loss of confidence from a key market participant.

Keywords

Jade Biosciences, Deep Track Capital, Schedule 13G, Ownership Change, Institutional Investor, Divestment, Common Stock, Biotechnology